Multicenter, Open-Label, Interventional Study on the Safety and Tolerability of Oxymetazoline and Energy-Based Therapy in Subjects With Rosacea
Phase of Trial: Phase IV
Latest Information Update: 06 Sep 2019
Price : $35 *
At a glance
- Drugs Oxymetazoline (Primary)
- Indications Rosacea
- Focus Adverse reactions; Therapeutic Use
- Sponsors Aclaris Therapeutics
- 27 Jun 2018 Status changed from active, no longer recruiting to completed.
- 04 May 2018 Planned End Date changed from 6 May 2018 to 29 May 2018.
- 04 May 2018 Planned primary completion date changed from 6 May 2018 to 29 May 2018.